XBI - Bellicum: Moving Toward MAA Submission For Rivo-Cel
Today, we want to share our analysis of Bellicum Pharmaceuticals (BLCM) with you. Over the last year, its stock largely fluctuated, falling from ~ $7 in September 2018 to $0.78 in August 2019. Recently, the company’s stock price grew by more than 20% after Baker Bros. disclosed its stake in the company. In this article, we intend to review recent developments and pipeline updates and discuss what shareholders can expect going forward.
Company description
Bellicum Pharmaceuticals is a clinical-stage biotechnology company that concentrates on developing novel therapeutics for the treatment of hematological cancers,